National Center for Complementary & Integrative Health; Notice of Closed Meeting, 53334 [2021-20879]
Download as PDF
<![CDATA[
53334
Federal Register / Vol. 86, No. 184 / Monday, September 27, 2021 / Notices
and Research Support Awards., National
Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: September 22, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–20885 Filed 9–24–21; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Development of a
Bispecific T Cell Engager for the
Treatment and Cure of HIV–1
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
ACTION:
National Center for Complementary &
Integrative Health; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
lotter on DSK11XQN23PROD with NOTICES1
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; Neural Mechanisms
of Force-Based Manipulations: High Priority
Research Networks.
Date: October 29, 2021.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Complementary
and Integrative Health, Democracy II, 6707
Democracy Blvd., Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sonia Elena Nanescu,
Ph.D., Scientific Review Officer, Office of
Scientific Review, Division of Extramural
Activities, NCCIH/NIH, 6707 Democracy
Boulevard, Suite 401, Bethesda, MD 20892–
5475, sonia.nanescu@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: September 22, 2021.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–20879 Filed 9–24–21; 8:45 am]
BILLING CODE 4140–01–P
18:08 Sep 24, 2021
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this notice to Gilead Sciences,
Inc. (‘‘Gilead’’) located in Foster City,
CA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before October 12, 2021 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Rose M. Freel, Ph.D., Senior
Licensing and Patenting Manager, NCI
Technology Transfer Center, 8490
Progress Drive, Suite 400, Frederick, MD
21701 (for business mail), Telephone:
(301)624–8775; Email: rose.freel@
nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
National Institutes of Health
VerDate Sep<11>2014
National Institutes of Health,
HHS.
Jkt 253001
Intellectual Property
United States Provisional Patent
Application No. 61/347,088, filed May
21, 2010 and entitled ‘‘High-affinity
fully functional soluble single-domain
human CD4, antibodies, and related
fusion proteins’’ [HHS Reference No. E–
103–2010/0–US–01];
PCT Patent Application PCT/US2011/
037439, filed May 20, 2011 and entitled
‘‘High-affinity fully functional soluble
single-domain human CD4, antibodies,
and related fusion proteins’’ [HHS
Reference No. E–103–2010/0–PCT–02];
United States Patent No. 8,911,728,
granted December 16, 2014,
corresponding to U.S. Application No.
13/699,535, filed January 11, 2013,
entitled ‘‘High-affinity fully functional
soluble single-domain human CD4,
antibodies, and related fusion proteins’’
[ HHS Reference No. E–103–2010–1–
US–03]; and
European Patent Application No.
21185510.1, filed July 14, 2021, entitled
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
‘‘High-affinity fully functional soluble
single-domain human CD4, antibodies,
and related fusion proteins’’ [HHS
Reference No. E–103–2010–1–EP–04].
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of the Licensed Patent Rights for the
following: ‘‘For use in an HIV Bispecific
T cell engager construct comprising the
CD4 mD1 which will be utilized in
therapeutic regimens to treat and cure
people living with HIV.’’
This technology discloses highly
soluble and stable single-domain sCD4
proteins that have therapeutic potential
for inhibition of HIV–1 viral entry into
cells. CD4 is a glycoprotein present on
the surface of mature CD4+ T cells and
is the primary receptor allowing the
entry of HIV–1 into cells. The
interaction between the CD4 protein on
the cell surface and the viral envelope
glycoprotein is key for infecting a cell.
As a result, the single-domain sCD4
proteins described in this invention
have potential uses in a variety of
therapeutic strategies attempting to
prevent the interaction between cellular
CD4 and the viral envelope and
therefore, inhibition of viral entry.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
E:\FR\FM\27SEN1.SGM
27SEN1
]]>Agencies
[Federal Register Volume 86, Number 184 (Monday, September 27, 2021)]
[Notices]
[Page 53334]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-20879]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Complementary & Integrative Health; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Complementary and
Integrative Health Special Emphasis Panel; Neural Mechanisms of
Force-Based Manipulations: High Priority Research Networks.
Date: October 29, 2021.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Center for Complementary and Integrative Health,
Democracy II, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sonia Elena Nanescu, Ph.D., Scientific Review
Officer, Office of Scientific Review, Division of Extramural
Activities, NCCIH/NIH, 6707 Democracy Boulevard, Suite 401,
Bethesda, MD 20892-5475, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.213,
Research and Training in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: September 22, 2021.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-20879 Filed 9-24-21; 8:45 am]
BILLING CODE 4140-01-P
